Evidence map›Paper›PMID 39990495›Full record

ArticlebioRxiv : the preprint server for biology2025

A Massively Parallel CRISPR-Based Screening Platform for Modifiers of Neuronal Activity.

Steven C Boggess, Vaidehi Gandhi, Ming-Chi Tsai, Emily Marzette, Noam Teyssier, Joanna Yu-Ying Chou, Xiaoyu Hu, Amber Cramer, Lin Yadanar, Kunal Shroff and 5 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Steven C BoggessInstitute for Neurodegenerative Diseases, University of California, San Francisco, San Francisco, CA, USA.
Vaidehi GandhiInstitute for Neurodegenerative Diseases, University of California, San Francisco, San Francisco, CA, USA.
Ming-Chi TsaiDepartment of Neuroscience, Genentech, South San Francisco, CA, USA.
Emily MarzetteWeill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Noam TeyssierInstitute for Neurodegenerative Diseases, University of California, San Francisco, San Francisco, CA, USA.
Joanna Yu-Ying ChouInstitute for Neurodegenerative Diseases, University of California, San Francisco, San Francisco, CA, USA.
Xiaoyu HuDepartment of Functional Genomics, Genentech, South San Francisco, CA, USA.
Amber CramerDepartment of Neuroscience, Genentech, South San Francisco, CA, USA.
Lin YadanarInstitute for Neurodegenerative Diseases, University of California, San Francisco, San Francisco, CA, USA.
Kunal ShroffInstitute for Neurodegenerative Diseases, University of California, San Francisco, San Francisco, CA, USA.
Claire G JeongDepartment of Neuroscience, Genentech, South San Francisco, CA, USA.
Celine EidenschenkDepartment of Functional Genomics, Genentech, South San Francisco, CA, USA.
Jesse E HansonDepartment of Neuroscience, Genentech, South San Francisco, CA, USA.
Ruilin TianInstitute for Neurodegenerative Diseases, University of California, San Francisco, San Francisco, CA, USA.
Martin KampmannInstitute for Neurodegenerative Diseases, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-3819-7019

Funding

Uncovering the Genetic Mechanisms of the Chromosome 17q21.31 Tau Haplotype on Neurodegeneration Risk in FTD and PSPU54NS123746 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GRINBERG, LEA TENENHOLZ · 2021 to 2025
$9.4M
Illumina NovaSeq 6000 Sequencing SystemS10OD028511 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHOW, ERIC D · 2020 to 2020
$583k
NIH HHS S10 OD028511NINDS NIH HHS U54 NS123746
6 · The paper itself

Abstract

Understanding the complex interplay between gene expression and neuronal activity is crucial for unraveling the molecular mechanisms underlying cognitive function and neurological disorders. Here, we developed pooled screens for neuronal activity, using CRISPR interference (CRISPRi) and the fluorescent calcium integrator CaMPARI2. Using this screening method, we evaluated 1343 genes for their effect on excitability in human iPSC-derived neurons, revealing potential links to neurodegenerative and neurodevelopmental disorders. These genes include known regulators of neuronal excitability, such as TARPs and ion channels, as well as genes associated with autism spectrum disorder and Alzheimer's disease not previously described to affect neuronal excitability. This CRISPRi-based screening platform offers a versatile tool to uncover molecular mechanisms controlling neuronal activity in health and disease.

Identifiers

PMID39990495
PMCPMC11844385

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.